Harbour BioMed gets FDA nod to begin clinical trial for HBM4003 in cancer

Harbour BioMed has secured approval from the US Food and Drug Administration (FDA) to move ahead with clinical studies in the US for its anti-CTLA-4 antibody HBM4003 for the treatment of cancer.